Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rang in Aktien #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Aktienkurs
$0.2483
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$2.30M
Veränderung (1 Tag)
-3.39%
Veränderung (1 Jahr)
-89.01%
Land
US
Handel Ensysce Biosciences, Inc. (ENSC)

Kategorie

Healthcare
Gewinn für Ensysce Biosciences, Inc. (ENSC)
Gewinn im Jun 2026 TTM: $-12.62M
Laut den aktuellen Finanzberichten von Ensysce Biosciences, Inc. betragen die aktuellen Gewinne des Unternehmens $-12.62M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-10.63M, eine Steigerung gegenüber dem Gewinn im Jahr 2022, der $-24.21M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Ensysce Biosciences, Inc. von 2017 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $-12.62M 58.06%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -41,883.41%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 24,352.67%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,551.44%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 31,713.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH